Genor Biopharma Holdings Limited

SEHK:6998 Stock Report

Market Cap: HK$635.9m

Genor Biopharma Holdings Management

Management criteria checks 2/4

Genor Biopharma Holdings' CEO is Feng Guo, appointed in Apr 2020, has a tenure of 4.08 years. total yearly compensation is CN¥32.18M, comprised of 14% salary and 86% bonuses, including company stock and options. directly owns 1.16% of the company’s shares, worth HK$7.36M. The average tenure of the management team and the board of directors is 3.8 years and 2.5 years respectively.

Key information

Feng Guo

Chief executive officer

CN¥32.2m

Total compensation

CEO salary percentage14.0%
CEO tenure4.1yrs
CEO ownership1.2%
Management average tenure3.8yrs
Board average tenure2.5yrs

Recent management updates

Recent updates

We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully

Dec 29
We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully

We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely

Dec 21
We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely

Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?

Sep 05
Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?

We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth

Dec 03
We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation

Aug 28
Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation

Is JHBP (CY) Holdings (HKG:6998) In A Good Position To Invest In Growth?

May 10
Is JHBP (CY) Holdings (HKG:6998) In A Good Position To Invest In Growth?

CEO Compensation Analysis

How has Feng Guo's remuneration changed compared to Genor Biopharma Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-CN¥674m

Sep 30 2023n/an/a

-CN¥637m

Jun 30 2023n/an/a

-CN¥599m

Mar 31 2023n/an/a

-CN¥665m

Dec 31 2022CN¥32mCN¥5m

-CN¥730m

Sep 30 2022n/an/a

-CN¥800m

Jun 30 2022n/an/a

-CN¥870m

Mar 31 2022n/an/a

-CN¥868m

Dec 31 2021CN¥41mCN¥5m

-CN¥865m

Compensation vs Market: Feng's total compensation ($USD4.44M) is above average for companies of similar size in the Hong Kong market ($USD233.89K).

Compensation vs Earnings: Feng's compensation has been consistent with company performance over the past year.

CEO

Feng Guo (53 yo)

4.1yrs

Tenure

CN¥32,177,000

Compensation

Dr. Feng Guo Ph D., serves as Chairman of the Board for Genor BioPharma Co., Ltd. since November 2021.He serves as Chairman at Genor Biopharma Holdings Limited since November 02, 2021. Dr. Guo has been th...

Leadership Team

NamePositionTenureCompensationOwnership
Feng Guo
CEO & Chairman4.1yrsCN¥32.18m1.16%
CN¥ 7.4m
Chengyi Weng
Vice President of Financeno datano datano data
Qibin Liang
Chief Technology Officer2.6yrsno datano data
Shuhua Han
Chief Scientist3.3yrsno datano data
Xiaojing Zhu
Vice President of Compliance & Administrationno datano datano data
Tong Li
Chief Medical Officer3.8yrsno datano data
Tak Wai Ip
Company Secretary1.9yrsno datano data
Jun Lin
Vice President of Quality Analysis4.3yrsno datano data
Qingtang Duan
General Manager of Yuxi Genor4.8yrsno datano data

3.8yrs

Average Tenure

53.5yo

Average Age

Experienced Management: 6998's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Feng Guo
CEO & Chairman4.1yrsCN¥32.18m1.16%
CN¥ 7.4m
David J. Kerr
Member of Scientific Advisory Board2.4yrsno datano data
Leonard B. Saltz
Member of Scientific Advisory Board2.4yrsno datano data
Wen Chen
Independent Non-Executive Director3.9yrsCN¥420.00kno data
Alex A. Adjei
Member of Scientific Advisory Board2.4yrsno datano data
Edwin Fung
Independent Non-Executive Director3.9yrsCN¥420.00kno data
Honghao Zhou
Independent Non-Executive Director3.7yrsCN¥420.00kno data
Dong Lyu
Non Executive Director2.5yrsno datano data
Zhijian Chen
Chairman of Scientific Advisory Board3yrsno datano data
Yangxin Fu
Member of Scientific Advisory Board2.4yrsno datano data
John F. Seymour
Member of Scientific Advisory Board2.4yrsno datano data
John R. Zalcberg
Member of Scientific Advisory Board2.4yrsno datano data

2.5yrs

Average Tenure

56.5yo

Average Age

Experienced Board: 6998's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.